WHO (2021) Hepatitis C fact sheet
Google Scholar
RKI (2021) Epidemiol Bull 28:1–22
Google Scholar
Zeuzem S (2017) Treatment options in hepatitis C. Dtsch Arztebl Int 114:11–21
PubMed
PubMed Central
Google Scholar
Sarrazin C, Zimmermann T, Zeuzem S (2020) Z Gastroenterol 58:1107–1108
Article
Google Scholar
Polaris Observatory HCVC (2017) Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2:161–176
Article
Google Scholar
Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV (2017) HCV cure and reinfection among people with HIV/HCV coinfection and people who inject drugs. Curr HIV/AIDS Rep 14:110–121
Article
Google Scholar
Simmons B, Saleem J, Heath K, Cooke GS, Hill A (2015) Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis 61:730–740
CAS
Article
Google Scholar
Calvaruso V, Craxi A (2020) Hepatic benefits of HCV cure. J Hepatol 73:1548–1556
CAS
Article
Google Scholar
Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A et al (2018) Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 155:411–421.e4
CAS
Article
Google Scholar
Zimmermann T, Jansen PL, Sarrazin C, Vollmar J, Zeuzem S (2018) Z Gastroenterol 56:e53–e115
Article
Google Scholar
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH et al (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364:2405–2416
CAS
Article
Google Scholar
Poordad F, McCone J Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS et al (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195–1206
CAS
Article
Google Scholar
Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N et al (2015) Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 373:2599–2607
CAS
Article
Google Scholar
Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S et al (2015) Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373:2608–2617
CAS
Article
Google Scholar
Fachinformation: Epclusa® 400 mg/100 mg Filmtabletten. Juli 2021
Fachinformation: Maviret® 100 mg/40 mg Filmtabletten. Juni 2021
Fachinformation: Harvoni® 90 mg/400 mg Filmtabletten. September 2021
DGVS. Online-Vorabveröffentlichung des Therapieteils im Rahmen Aktualisierung der S3-Leitlinie zur „Hepatitis-C-Virus (HCV)-Infektion; Prophylaxe, Diagnostik und Therapie“. Dezember 2016
Fachinformation: Zepatier® 50 mg/100 mg Filmtabletten. November 2020
Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A et al (2017) Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology. https://doi.org/10.1053/j.gastro.2017.11.007
Article
PubMed
Google Scholar
Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M et al (2017) Sofosbuvir, Velpatasvir, and Voxilaprevir for previously treated HCV infection. N Engl J Med 376:2134–2146
CAS
Article
Google Scholar
Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, Garcia-Samaniego J et al (2019) Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J Hepatol 71:666–672
CAS
Article
Google Scholar
Degasperi E, Spinetti A, Lombardi A, Landonio S, Rossi MC, Pasulo L et al (2019) Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol 71:1106–1115
CAS
Article
Google Scholar
Sarrazin C, Zimmerman T, Berg T, Neumann U, Schirmacher P, Schmitt H et al (2017) S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion“ AWMF-Register-Nr.: 021/012
Google Scholar
Belperio PS, Shahoumian TA, Mole LA, Backus LI (2017) Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology 66:27–36
CAS
Article
Google Scholar
Mucke MM, Backus LI, Mucke VT, Coppola N, Preda CM, Yeh ML et al (2018) Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 3:172–180
Article
Google Scholar
Jonas MM, Squires RH, Rhee SM, Lin CW, Bessho K, Feiterna-Sperling C et al (2020) Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study. Hepatology 71:456–462
CAS
Article
Google Scholar
www.hep-druginteractions.org. Zugegriffen: 21. Nov 2021
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karziome, Langversion 2.0, 2021, AWMF Registernummer: 032/053OL. https://www.leitlinienprogramm-onkologie.de/leitlinien/hcc-und-billiäre-karzinome. Zugegriffen: 21. Nov 2021